Uniworth International Limited appointed Kishor Jhunjhunwala as an additional non-executive independent director. The board approved the five-year term effective September 4, 2026, subject to shareholder approval at the ensuing annual general meeting.

The company also accepted the resignation of Vivek Chaudhary from the position of independent director, effective close of business on September 4, 2026. Chaudhary cited pre-occupation elsewhere as the reason for his departure.

Board Composition Changes

The appointment and resignation were approved during a board meeting held on September 4, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Jhunjhunwala, a qualified Chartered Accountant with experience in account, finance, and management, satisfies the independence criteria under the Companies Act, 2013 and SEBI LODR Regulations. He is not related to any existing director of the company.

Chaudhary ceases to be a member of the Audit Committee, Stakeholder & Relationship Committee, and Nomination & Remuneration Committee upon his resignation. He confirmed there are no material reasons for his resignation other than those stated in his letter dated September 3, 2026.

The board will reconstitute various committees to comply with regulatory requirements following these changes.

Uniworth International Limited reported a standalone loss of ₹39.40 lakh for the quarter ended June 30, 2026, compared to a loss of ₹38.81 lakh in the corresponding period of FY25. The company’s consolidated loss widened slightly to ₹39.65 lakh from ₹38.81 lakh in Q1FY25.

The Board of Directors approved the unaudited financial results on August 14, 2026. A critical disclosure in the filing notes that the company’s business activities have been suspended for a long duration, resulting in nil income from operations for both standalone and consolidated entities.

Financial Performance

With no operational revenue generated, the company’s expenses were limited to statutory and administrative overheads. Standalone total expenses rose marginally to ₹39.40 lakh from ₹38.81 lakh in Q1FY25. Finance costs accounted for ₹38.25 lakh of these expenses in both standalone and consolidated figures.

Consolidated expenses totaled ₹39.65 lakh, including a minor contribution from a subsidiary, Uniworth Biotech Limited, which reported a net loss of ₹0.25 lakh and nil revenue. The consolidated loss attributable to owners of the parent was ₹39.10 lakh.

Balance Sheet and Regulatory Notes

The auditor’s review report highlighted several unprovided accounts receivable, including trade receivables of ₹3,010.57 lakh and other financial assets of ₹227.73 lakh. No interest provision was made for borrowings from Punjab National Bank, Indusind Bank, and HSBC Bank, although simple interest provisions were recorded for borrowings from Centurion Bank and Punjab & Sind Bank.

The company has not recognized deferred tax assets due to consistent losses and uncertainty regarding future profits. Additionally, applications have been filed with the Reserve Bank of India for the extension or set-off of certain overdue bills.